Natco Pharma gets USFDA EIR for Telangana facility

Written by Ruchika Sharma Published On 2020-04-27T10:49:35+05:30 | Updated On 27 April 2020 10:49 AM IST

Natco Pharma gets USFDA EIR for Telangana facility

Hyderabad: Natco Pharma Limited has announced the successful closure of inspection with an Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (FDA) for the pre-approval inspection conducted at its drug formulations facility in Kothur village, Telangana, India, during the period from 2nd March to 6th March 2020.

Natco Pharma Limited was incorporated in Hyderabad in the year 1981 with an initial investment of INR 3.3 million.

With a modest beginning of operations as a single unit with 20 employees, Natco today has seven manufacturing facilities spread across India with dedicated modern research laboratories, capabilities in New Drug Development, etc.

natco-pharmausfdaeir

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751